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Recent studies have begun to reveal critical roles of microRNAs (miRNAs) in the pathogenesis of cardiac hyper-
trophy and dysfunction. In this study, we tested whether a transforming growth factor-β (TGF-β)-regulated miRNA 
played a pivotal role in the development of cardiac hypertrophy and heart failure (HF). We observed that miR-27b 
was upregulated in hearts of cardiomyocyte-specific Smad4 knockout mice, which developed cardiac hypertrophy. 
In vitro experiments showed that the miR-27b expression could be inhibited by TGF-β1 and that its overexpression 
promoted hypertrophic cell growth, while the miR-27b suppression led to inhibition of the hypertrophic cell growth 
caused by phenylephrine (PE) treatment. Furthermore, the analysis of transgenic mice with cardiomyocyte-specific 
overexpression of miR-27b revealed that miR-27b overexpression was sufficient to induce cardiac hypertrophy and 
dysfunction. We validated the peroxisome proliferator-activated receptor-γ (PPAR-γ) as a direct target of miR-27b 
in cardiomyocyte. Consistently, the miR-27b transgenic mice displayed significantly lower levels of PPAR-γ than the 
control mice. Furthermore, in vivo silencing of miR-27b using a specific antagomir in a pressure-overload-induced 
mouse model of HF increased cardiac PPAR-γ expression, attenuated cardiac hypertrophy and dysfunction. The re-
sults of our study demonstrate that TGF-β1-regulated miR-27b is involved in the regulation of cardiac hypertrophy, 
and validate miR-27b as an efficient therapeutic target for cardiac diseases. 
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Introduction
Heart failure (HF) is one of the most frequent causes 
of death worldwide.
 The underlying causes of HF are 
diverse, but HF is often associated with cardiac hyper-
trophy. Numerous regulatory pathways are implicated 
in the transduction of hypertrophic signaling [1]. The 
members of the transforming growth factor-β (TGF-β) 
superfamily signal through receptor serine/threonine 
kinases and intracellular Smad proteins [2], and play a 
complex and often contradictory role in the development 
of cardiac hypertrophy [3]. Although many in vitro and 
in vivo studies have shown that TGF-β1 overexpression 
leads to cardiac hypertrophy and HF [4, 5], recent studies 
have shown that TGF-β signaling may play a role in the 
protective mechanism in cardiac hypertrophy [6-9]. Our 
previous study reveals that Smad4 deletion in cardio-
myocytes results in cardiac hypertrophy characterized by 
enlargement of cardiomyocytes, age-associated fibrosis 
and re-expression of certain fetal genes [6]. Growth dif-
ferentiation factor 15 (GDF15), a member of the TGF-β 
superfamily, antagonizes the hypertrophic response pos-
sibly through a mechanism involving the Smad proteins 
[7, 8]. In addition, cardiac-specific overexpression of 
bone morphogenetic protein-10 (BMP-10) impairs the 
postnatal cardiac hypertrophic growth by activation of www.cell-research.com | Cell Research
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Smad1/5/8-mediated signaling [9]. However, the molec-
ular mechanisms that regulate the cellular responses of 
cardiomyocytes to TGF-β signaling, which antagonizes 
cardiac hypertrophy, still have still not been elucidated. 
MicroRNAs (miRNAs) are small, endogenous non-
coding RNAs, which are approximately 22 nucleotides 
in length. The miRNA inhibit the expression of specific 
genes by either degrading the target mRNA or direct 
translational inhibition [10]. Increasing evidences have 
revealed that miRNAs play important roles in cardiac hy-
pertrophy and dysfunction [11-14]. Several studies have 
shown that miRNA expressions are altered in mouse and 
human HFs. The cardiac-specific knockout of Dgcr8 or 
Dicer, which are essential for the biogenesis and process-
ing of miRNA, leads to a rapidly progressive dilated 
cardiomyopathy, HF and postnatal lethality [11-13]. The 
cardiac overexpression of miR-195, which is upregulated 
during cardiac hypertrophy, induces pathological cardiac 
growth and HF in transgenic mice [14]. Similarly, car-
diac overexpression of miR-208a, which is located in the 
non-coding region of the α-myosin heavy chain (α-MHC) 
gene, is sufficient to induce hypertrophy, while analyses 
of miR-208a-deficient mice exhibited defects in stress-
dependent cardiac growth and proper cardiac conduction 
[15, 16]. Previous studies have also shown that forced 
expression of miR-1 or miR-133 prevented hypertro-
phic cell growth in cultured cardiomyocytes and cardiac 
hypertrophy in transgenic mice [17, 18]. However, the 
function of TGF-β-regulated miRNAs in cardiac hyper-
trophy has not yet been reported. 
In this study, we performed miRNA northern blot to 
examine whether the expression patterns of miRNAs 
whose expression are changed in mouse models of car-
diac hypertrophy [14, 17, 19] were altered in hypertro-
phic Smad4-deficient hearts. We observed that miR-27b 
was significantly upregulated in Smad4 mutant hearts, 
and miR-27b could be inhibited by TGF-β1. We also 
observed that overexpression of miR-27b in primary 
cultured cardiomyocytes promoted hypertrophic cell 
growth by targeting the peroxisome proliferator-activated 
receptor-γ (PPAR-γ). Consequently, miR-27b transgenic 
mice developed dilated cardiomyopathy and cardiac 
dysfunction. In addition, in vivo administration of antag-
omir-27b in a transverse aortic constriction (TAC) mouse 
model attenuated cardiac hypertrophy and dysfunction, 
suggesting miR-27b as a therapeutic target for HF.
Results
miR-27b is upregulated in Smad4-deficient hearts and 
downregulated by TGF-β1
Targeted deletion of Smad4 in cardiomyocytes induces 
cardiac hypertrophy and HF [6]. Our previous study has 
shown that the cluster of miR-23a/miR-27a/miR-24-
2 can be inhibited by TGF-β1 [20]. We hypothesized 
that the cluster of miR-23b/miR-27b/miR-24-1, which 
was frequently dysregulated in mouse models of cardiac 
hypertrophy [14, 19], could also be inhibited by TGF-β 
signaling. We first performed miRNA northern blot to 
examine the expression of these miRNAs, and found that 
miR-27b expression was significantly increased in Smad4 
mutant hearts (Figure 1A); the result was also confirmed 
by real-time PCR (Supplementary information, Figure 
S1A). We further examined the expression of miR-23b 
and miR-24-1 using real-time PCR, and found that they 
were all upregulated in Smad4 mutants (Supplementary 
information, Figure S1B). The expression of miR-27b in 
a wide range of tissues was also shown by northern blot 
(Figure 1B). To confirm that miR-27b was regulated by 
TGF-β signaling, we treated neonatal cardiomyocytes 
with TGF-β1. Real-time PCR and northern blot results 
showed that pre-miR-27b and mature miR-27b were 
downregulated when treated with TGF-β1 (Figure 1C 
and 1D), implying that cardiac miR-27b was inhibited 
by TGF-β1. The efficient response of cardiomyocyte to 
TGF-β1 was confirmed by plasminogen activator inhibi-
tor-1 (PAI-1) upregulation (Figure 1C and 1D). The ex-
pressions of miR-23b and miR-24-1 were also inhibited 
by TGF-β1 (Supplementary information, Figure S1C). 
To examine whether miR-27b could be regulated by 
TGF-β1 at the transcriptional level, we used the 2 900-
bp promoter of miR-27b, which contained a potential 
Smad-binding site (CAGACAT), to drive expression of 
the luciferase reporter gene in NIH3T3 cells. Treatment 
with TGF-β1 significantly inhibited the miR-27b pro-
moter activity, whereas no effect was observed when the 
construct contained the promoter with a mutated Smad-
binding site (Figure 1E). All these data corroborate the 
hypothesis that TGF-β1 regulated miR-27b transcription.
miR-27b overexpression promotes hypertrophic growth 
of cardiomyocytes
To investigate the potential function of miR-27b in 
cardiomyocytes, we performed gain-of-function and 
loss-of-function experiments by using cultured rat neo-
natal cardiomyocytes. We designed two adenoviral vec-
tors encoding sense (Ad-miR-27b) and antisense miR-
27b (Ad-anti-miR-27b), respectively. Real-time PCR and 
northern blot analysis showed efficient overexpression 
of the pre- and mature miR-27b in Ad-miR-27b-infected 
cardiomyocytes and efficient knockdown of endogenous 
mature miR-27b in cardiomyocytes with Ad-anti-miR-
27b (Figure 2A and 2B).
The cardiomyocytes infected with adenoviruses for Function of miR-27b in cardiac hypertrophy
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Figure 1 miR-27b upregulated in the hearts of cardiomyocyte-specific Smad4-deficient mice was inhibited by TGF-β1. (A) 
Northern blot showed that miR-27b was greatly increased in Smad4
Flox/Flox; α-MHC-Cre mutant hearts (Mut) compared with 
Smad4
Flox/+; α-MHC-Cre controls (Con). A RNA probe against the small housekeeping RNA U6 (106 nt) was used as a loading 
control. Lower: quantitative analysis of fold change in expression of miRNAs. *P < 0.05 relative to control mice. (B) Northern 
blot showed that miR-27b was expressed in multiple tissues of a 1-month-old mouse. Lower: quantitative analysis of tissue 
profile for miR-27b. (C) Real-time PCR showed that pre-miR-27b was decreased in cardiomyocytes treated with TGF-β1 for 
12 and 24 h, and the TGF-β1 target molecule, Pai-1, was significantly increased in cardiomyocytes treated with TGF-β1. (D) 
Northern blot revealed that miR-27b was significantly downregulated upon the treatment of TGF-β1 for 12 and 24 h, along 
with the upregulation of PAI-1 shown by western blot. (E) NIH-3T3 cells transfected with reporter vectors containing native or 
mutated miR-27b promoter were treated with or without TGF-β1 (5 ng/ml) for 24 h, and then harvested for luciferase assay. 
pGL-3 basic and pGL3-CAGA were used as negative and positive controls, respectively. *P < 0.05 relative to respective con-
trols. 
48 h were immunostained for α-actinin to study the mor-
phological changes. Immunostaining revealed that car-
diomyocytes treated with phenylephrine (PE) or infected 
with Ad-miR-27b were significantly larger than cardio-
myocytes infected with adenoviruses encoding green 
fluorescent protein (Ad-GFP) (Figure 2C-2E). Hypertro-
phy induced by miR-27b overexpression was comparable 
to that induced by adrenergic agonist PE (Figure 2D and www.cell-research.com | Cell Research
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2E). Conversely, knockdown of miR-27b partially res-
cued the hypertrophic effects of PE treatment and miR-
27b overexpression (Figure 2F-2I). Cardiac hypertrophy 
is always accompanied by upregulation of fetal genes, 
such as atrial natriuretic factor (ANF) and skeletal mus-
cle and cardiac actin (SKA). Real-time PCR showed that 
miR-27b overexpression could significantly upregulate 
ANF and SKA transcripts, while miR-27b knockdown 
could partially rescue the upregulation of these genes in 
the cardiomyocytes treated with PE or cardiomyocytes 
overexpressing miR-27b (Figure 2J and 2K). Quantita-
tive assessment of cardiomyocyte proliferation by using 
Figure 2 Overexpression of miR-27b promoted hypertrophic growth of cardiomyocytes. (A) Real-time PCR showed that miR-
27b adenovirus effectively increased the expression level of pre-miR-27b. (B) Northern blot and quantification results showed 
that miR-27b adenovirus increased the miR-27b level in cardiomyocytes, while anti-miR-27b adenovirus decreased the en-
dogenous expression level of miR-27b. (C-H) Isolated rat neonatal cardiomyocytes were infected with Ad-miR-27b, Ad-anti-
miR-27b or control adenoviruses, and treated with or without PE. Cardiomyocytes were stained for GFP (green) and α-actinin 
(red). DAPI staining was done to visualize the nuclei (blue). Scale bar, 15 µm. (I) Fold change in mean cell surface area of 
α-actinin-immunostained cardiomyocytes (n = 120 cells/condition). (J, K) ANF and SKA transcripts were examined by real-
time PCR. *P < 0.05 relative to respective controls. 
aP < 0.05 vs Ad-GFP treated with PE. 
bP < 0.05 vs miR-27b overexpres-
sion.Function of miR-27b in cardiac hypertrophy
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Ki67 immunofluorescence showed that cardiomyocyte 
proliferation was not affected by miR-27b overexpres-
sion (Supplementary information, Figure S2A). These 
findings indicate that miR-27b could induce hypertrophy 
of cardiomyocytes.
Cardiomyocyte-specific overexpression of miR-27b in-
duces cardiac hypertrophy
To investigate the role of miR-27b in cardiac remod-
eling in vivo, we generated two transgenic mouse lines 
carrying the mouse miR-27b DNA under the control of 
α-MHC promoter. Northern blot results revealed that 
miR-27b was successfully overexpressed in the trans-
genic hearts from lines #1 and #2 (3-4-fold increase, 
Figure 3A). We selected line #1 for further studies. All 
these miR-27b transgenic mice were born normally and 
had normal cardiac structure (data not shown). They 
survived to adulthood and were fertile. However, 30% of 
transgenic mice died suddenly between 6 and 12 months 
of age. The miR-27b transgenic mice developed signifi-
cant cardiac hypertrophy at 3 months of age (Figure 3B). 
They showed higher heart weight/body weight (HW/
BW) and heart weight/tibia length (HW/TL) ratios than 
the littermate controls (Figure 3C). The fetal genes such 
as ANF, β-MHC and SKA were also significantly up-
regulated in the heart tissues of miR-27b transgenic mice 
(Figure 3D).
We performed further studies to ascertain whether the 
increase of the heart size was due to cell growth (increase 
in cell size) or cell proliferation (increase in cell num-
ber). Cardiomyocyte proliferation was assessed by BrdU 
staining. The cardiomyocyte proliferation in the miR-27b 
transgenic mice and the littermate controls were not sig-
nificantly different (Supplementary information, Figure 
S2B). Cross-sections of hearts confirmed left ventricle 
Figure 3 Overexpression of miR-27b induced cardiac hypertro-
phy in vivo. (A) Northern blots and quantification data (n = 3) 
showed an approximately 3-4-fold increase of miR-27b expres-
sion in hearts of miR-27b transgenic (Tg) mice compared with 
control (Con) littermates. A RNA probe against U6 was used as 
a loading control. (B) Gross morphology of miR-27b Tg hearts 
was enlarged compared with control hearts at 3 months. Scale 
bar, 5 mm. (C) Heart weight to body weight or tibia length of 
3-month-old miR-27b Tg mice (n = 7) was significantly higher 
than controls (n = 8). (D) Analysis of ANF, β-MHC and SKA by 
real-time PCR in hearts from miR-27b Tg and control mice (n = 
6/genotype). *P < 0.05 vs control mice.
Figure 4 Overexpression of miR-27b in vivo induced cardiac hy-
pertrophy. (A, B) Macroscopic view of H&E-stained transverse 
sections from control (A) and miR-27b Tg hearts (B). (C, D) Im-
munostaining with a rabbit polyclonal anti-laminin antibody was 
performed on transverse sections of myocardium from littermate 
control (C) and miR-27b Tg mice (D). (E, F) Representative im-
ages of isolated cardiomyocytes from 3-month-old littermate 
control (E) and miR-27b Tg mice (F). (G) Histological sections 
were detected by laminin staining to determine cell size. Mean 
cardiomyocyte cross-sectional area of miR-27b Tg hearts (n = 
500) was significantly larger than control cardiomyocytes (n = 
500). *P < 0.001. (H) The mean cell area of the cardiomyocytes 
(n = 150) isolated from 3-month-old miR-27b transgenic mice 
was greater than control cardiomyocytes (n = 150; *P < 0.001). 
Scale bars, A, B: 2 mm and C-F: 50 µm.www.cell-research.com | Cell Research
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Figure 5 Cardiac dysfunction in miR-27b transgenic mice. (A) Representative M-mode images of miR-27b Tg mice (right) 
and littermate controls (left). (B, C) Measurements of the LV wall thickness in systole (LVPWs) and diastole (LVPWd). (D, E) 
Measurements of the LV internal diameters in systole (LVIDs) and diastole (LVIDd). (F-H) Quantification of ratio of LV mass 
to body weight (LVM/BW), ejection fraction (EF) and fractional shortening (FS). Mean values ± SEM were determined by 
echocardiography. (I, J) Quantification of the LV diastolic end pressure (LVEDP), the mean arterial blood pressure (MAP) in 
hearts from miR-27b Tg mice and control mice at the age of 3 and 6 months. Mean values ± SEM were determined by hemo-
dynamic analysis. *P < 0.05, significantly different from age-matched controls. 
(LV) enlargement (Figure 4A and 4B), and showed that 
the cardiomyocytes of the transgenic mice were larger 
than those of the control mice using laminin immunohis-
tochemistry (Figure 4C and 4D). Quantitative measure-
ment of miR-27b transgenic cardiomyocytes revealed 
a 32% increase in cell cross-sectional area relative to 
controls (Figure 4G). We also measured the cell size of 
the individual cardiomyocytes in isolated adult myocyte 
preparations (Figure 4E and 4F). The mean cell area of 
the cardiomyocytes (n = 150) obtained from three-month-
old miR-27b transgenic mice (n = 4) was greater than that 
of those obtained from the control mice (Figure 4H).
These observations indicated that miR-27b overex-
pression in vivo is sufficient to induce cardiac hypertro-
phy, which may be largely due to the increased size of 
cardiomyocyte.
miR-27b transgenic mice developed impaired cardiac 
function
To evaluate the effect of miR-27b overexpression on 
cardiac function, we first assessed the LV dimensions 
and the systolic functions of 3-month-old and 6-month-Function of miR-27b in cardiac hypertrophy
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old miR-27b transgenic mice by using M-mode echocar-
diography (Figure 5A and Supplementary information, 
Table S1). We observed thinning of the LV walls (Figure 
5B and 5C), an increase in the LV internal diameter in 
diastole and systole (Figure 5D and 5E) and an increase 
in the ratio of the LV mass (LVM) to the body weight 
(BW) (Figure 5F). In addition, the ejection fraction (EF) 
showed a declining trend (Figure 5G). Fractional short-
ening (FS), an echocardiographic index of LV contractile 
function, was also decreased in the miR-27b transgenic 
mice (Figure 5H).
Functional invasive hemodynamic measurements 
were performed to confirm the occurrence of echocardio-
graphic alterations in miR-27b transgenic mice. The LV 
diastolic end pressure (LVEDP), measured after induc-
ing anesthesia and LV catheterization, was found to be 
increased (Figure 5I). The mean arterial blood pressure 
(MAP) was also slightly increased (Figure 5J). How-
ever, the heart rates and other hemodynamic variables 
of the control and transgenic mice were not different 
(Supplementary information, Table S2). All these results 
reflected the impairment of cardiac function in miR-27b 
transgenic mice.
PPAR-γ is a direct target of miR-27b in cardiomyocytes
To reveal the potential mechanism of miR-27b in 
cardiac hypertrophy, we screened the candidate miR-
27b target mRNAs that have been reported to be in-
volved in cardiac hypertrophy using a bioinformatic 
approach, as detailed at TargetScan (http://genes.mit.
edu/targetscan/). This analysis led to the identification 
of PPAR-γ, in which mRNA 3′-UTR regions comprise 
the seed sequences and flanking nucleotides matching 
miR-27b, which is highly conserved among the human, 
mouse, rat and dog species (Supplementary information, 
Figure S3A-S3C). To confirm whether PPAR-γ is a direct 
target of miR-27b, we performed luciferase reporter as-
says in HEK293 cells. Cotransfection of miR-27b with 
the luciferase reporter gene linked to the wild-type 3′-
UTR of PPAR-γ strongly inhibited the luciferase activity, 
while cotransfection with anti-miR-27b rescued this ef-
fect (Figure 6A). However, no effect was observed with 
the construct harboring a mutant segment of PPAR-γ 3′-
UTR (seed sequence 5′-ACUGUGA-3′ was mutated to 
5-′AGAAUUC-3′). Moreover, cotransfection of miR-24 
(control miRNA; not complementary to the 3′-UTR of 
PPAR-γ) with the wild-type PPAR-γ 3′-UTR construct 
did not alter the luciferase activity, indicating that miR-
27b specifically targeted PPAR-γ (Figure 6A). The RT-
PCR and real-time PCR results showed that the miR-27b 
overexpression did not affect the transcriptional level 
of PPAR-γ in cardiomyocytes (Figure 6B). However, 
the infection of HEK293 cells and rat neonatal cardio-
myocytes with Ad-miR-27b reduced the PPAR-γ protein 
levels, whereas knockdown of endogenous miR-27b in 
these cells increased the PPAR-γ protein levels (Figure 
6C). We further measured the PPAR-γ expression level 
in Smad4 mutant heart tissues, which showed increased 
miR-27b levels, and observed that PPAR-γ was signifi-
cantly decreased in Smad4 mutants (Figure 6D). Consis-
tently, PPAR-γ levels were significantly reduced in miR-
27b transgenic hearts (Figure 6E).
To test the effect of PPAR-γ inhibition on cardiomyo-
cytes, we infected cardiomyocytes with adenovirus that 
interfere with of PPAR-γ (Ad-si-PPAR-γ; Supplementary 
information, Figure S4A-S4C). Knockdown of PPAR-γ 
in cardiomyocyes increased the cell size (Supplementary 
information, Figure S4D) and upregulated the expression 
of fetal genes (Supplementary information, Figure S4E), 
indicating that PPAR-γ interference induced hypertrophy 
of cardiomyocytes.
Furthermore, we developed Ad-PPAR-γ to overex-
press PPAR-γ in cardiomyocytes. Western blot results 
showed that PPAR-γ was successfully overexpressed 
in cardiomyocytes infected by Ad-PPAR-γ (Figure 6F). 
In addition, PPAR-γ overexpression could reduce the 
increased cell surface area caused by miR-27b overex-
pression (Figure 6F). All these observations suggest that 
miR-27b acts as a negative regulator of PPAR-γ at post-
transcriptional levels, and PPAR-γ mediates the cardiac 
hypertrophic effect of miR-27b.
Inhibition of miR-27b attenuated cardiac hypertrophy 
and dysfunction in a TAC mouse model
To test whether miR-27b inhibition was truly benefi-
cial for cardiac diseases, we injected antagomir-27b into 
mice subjected to pressure overload of the LV by TAC 
and followed the disease for additional 3 weeks (Supple-
mentary information, Figure S5A). First, we tested the 
effect of antagomir-27b in vivo and found that mature 
miR-27b was significantly downregulated in hearts by 
antagomir-27b administration (Supplementary informa-
tion, Figure S5B). In addition, measurements of HW/BW, 
HW/TL, fetal genes and histological examination indi-
cated that antagomir-27b administration did not affect the 
morphology of hearts in unstressed mice (Supplementary 
information, Figure S5C-S5F). Expression levels of 
miR-27b were increased in mice after the TAC surgery 
(Figure 7A). The TAC-induced miR-27b overexpression 
was effectively downregulated by antagomir-27b treat-
ments as shown by real-time PCR (Figure 7B). In the 
myocardium, antagomir-27b treatment significantly re-
versed changes in PPAR-γ expression caused by pressure 
overload (Figure 7C). TAC-operated mice treated with www.cell-research.com | Cell Research
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Figure 6 PPAR-γ is a target of miR-27b in cardiomyocytes. (A) Dual luciferase activity assay of HEK293 cells cotransfected 
with a luciferase reporter plasmid containing the naive or mutant PPAR-γ 3′-UTR and a miR-27b or miR-24 expression plas-
mid or a miR-27b inhibitor. *P < 0.05 relative to respective controls. + Represents 200 ng/well and ++ represents 400 ng/well. 
(B) RT-PCR and real-time PCR showed that miR-27b did not affect the mRNA level of PPAR-γ. (C) Western blots for PPAR-γ 
proteins from HEK293 cells and cardiomyocytes infected with Ad-miR-27b or Ad-anti-miR-27b. Right: quantitative analysis 
of fold change in expression of PPAR-γ. (D) Western blot showed that PPAR-γ level was decreased in the heart tissues of 
Smad4-deficient mice. Right: quantitative analysis of fold change in the expression of Smad4 and PPAR-γ. (E) PPAR-γ was 
decreased in the heart tissues of miR-27b transgenic mice revealed by western blot. GAPDH was used as a loading control. 
Lower: quantitative analysis of fold change in the expression of PPAR-γ. (F) PPAR-γ overexpression rescued hypertrophic 
growth of cardiomyocytes caused by miR-27b overexpression. Upper: western blot for PPAR-γ proteins from cardiomyo-
cytes infected with Ad-PPAR-γ or Ad-GFP. Lower: Quantitative analysis of fold change in mean cell surface area of α-actinin-
immunostained cardiomyocytes infected with adenoviruses (n = 160 cells/condition). *P < 0.05 relative to Ad-GFP. 
aP < 0.05 
vs miR-27b overexpression.Function of miR-27b in cardiac hypertrophy
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saline displayed progressive cardiac hypertrophy and 
interstitial fibrosis, whereas TAC-operated mice treated 
with antagomir-27b showed significant attenuation of the 
effects (Figure 7D-7G). Analysis of cardiac function by 
echocardiography showed that antagomir-27b treatment 
significantly reversed LV wall thickness and LV mass 
and normalized fractional shortening (Figure 7H-7J and 
Supplementary information, Table S3).
Discussion
In this study, we investigated the physiological func-
tions of miR-27b and the molecular mechanisms by 
which miR-27b induces cardiac hypertrophy. The im-
portant novel findings of our study are as follows: (1) 
miR-27b is upregulated in Smad4-deficient hypertrophic 
heart; (2) miR-27b is significantly inhibited by TGF-
β1 in cardiomyocytes; (3) cardiac overexpression of 
miR-27b is sufficient to induce cardiac hypertrophy and 
dysfunction; (4) PPAR-γ, the target gene of miR-27b, is 
downregulated in miR-27b transgenic mice, and PPAR-γ 
overexpression could partially rescue the effects caused 
by miR-27b overexpression; (5) in vivo inhibition of 
miR-27b attenuates structural and functional deterio-
ration in a TAC-induced HF mouse model. Thus, our 
results provide the first and critical genetic evidences 
showing that TGF-β-regulated miR-27b plays an impor-
tant role in cardiac growth and hypertrophy.
Increasing evidences from experimental studies have 
shown that Smad-mediated responses to TGF-β signaling 
have cardioprotective effects in cardiac hypertrophy [21]. 
Cardiomyocyte-specific deletion of Smad4 induces car-
diac hypertrophy and HF [6], while transaortic constric-
tion leads to a significant increase in cardiac hypertrophy 
Figure 7 Antagomir-27b attenuated cardiac hypertrophy and dysfunction in a TAC mouse model. (A) Detection of miR-27b 
expression level in TAC models by real-time PCR. *P < 0.05 relative to control. (B) Detection of miR-27b expression level 3 
weeks after treatment with saline or antagomir-27b by real-time PCR. *P < 0.05 and **P < 0.01. (C) PPAR-γ expression level 
was determined in hearts by western blot (n = 3/condition). (D) Heart weight to body weight or tibia length of mice from sham 
(n = 11), TAC treated with saline (n = 7) or with antagomir-27b (n = 5). *P < 0.05 and **P < 0.01. (E) Histological analysis of 
hearts from different groups using masson staining and Laminin immunostaining. Scale bar, upper panel: 2 mm and middle 
and lower panel: 50 µm. (F) Analysis of ANF, BNP, β-MHC and α-MHC in hearts from different groups by real-time PCR (n = 
3/condition). *P < 0.05. (G) Cross-sectional areas were analyzed after laminin immunostaining (n = 400 cells/condition). *P < 
0.05 and **P < 0.01. (H-J) LVPWD, FS and LVM were analyzed from TAC mice treated with saline (n = 8) or antagomir-27b (n 
= 5). *P < 0.05.www.cell-research.com | Cell Research
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in the Smad3-deficient mice [22]. Studies on cardiomyo-
cyte-specific Smad5 mutant mice have also suggested 
that Smad5 is required for cardiac homeostasis [23]. In 
this study, we observed that miR-27b was upregulated in 
Smad4-deficient hypertrophic heart tissues. We also ob-
served that TGF-β1 significantly inhibited miR-27b at the 
transcriptional level. Furthermore, we provided the first 
direct evidence to prove that miR-27b overexpression is 
sufficient to induce cardiac hypertrophy both in vitro and 
in vivo. All these findings suggest that TGF-β signaling 
might protect cardiomyocytes from hypertrophic growth 
by downregulating miRNAs that cause cardiac hypertro-
phy when overexpressed. This new finding has increased 
our knowledge on the complex molecular mechanisms 
of TGF-β in maintaining cardiac homeostasis. Recent 
studies have shown that miRNA mediates TGF-β signal-
ing for modulating several biological processes [20, 24]. 
miR-23b cluster miRNAs, including miR-27b, have been 
shown to regulate liver stem cell differentiation by tar-
geting Smads [25]. Our data suggest that miR-23b cluster 
miRNAs could be inhibited by TGF-β1. Whether there is 
a reciprocal feedback loop between TGF-β signaling and 
miR-23b/miR-27b/miR-24-1 cluster in cardiomyocytes 
needs to be further investigated. 
It is noteworthy that miR-27b is frequently upregu-
lated in pressure-overloaded hypertrophic hearts [14, 
17, 19]. Recent studies also demonstrated that miR-27b 
displayed an overt myocardial expression during heart 
development [26]. However, the miR-27b function in 
cardiac hypertrophy has not been elucidated yet. In the 
present study, we elucidated the in vivo physiological and 
pathological consequences of miR-27b in cardiac hyper-
trophy using both gain-of-function and loss-of-function 
approaches. Most importantly, we performed curative 
experiment to demonstrate that miR-27b inhibition was 
indeed beneficial for pressure overload-induced cardiac 
hypertrophy and HF. Previous studies have revealed that 
a limited number of miRNAs may constitute new thera-
peutic targets for ischemic heart diseases [27-30] as well 
as hypertension-induced HFs [31, 32]. Our study showed 
that in vivo knockdown of miR-27b significantly attenu-
ated hypertrophic effects caused by pressure overload, 
providing a new potential therapeutic target for pressure 
overload heart diseases. 
In this study, we identified that PPAR-γ was the target 
of miR-27b and partially mediated cardiac hypertrophy 
that resulted form miR-27b overexpression. PPAR-γ is 
a well-known critical regulator during cardiac hypertro-
phy. PPAR-γ agonists inhibit mechanical stress-induced 
hypertrophy of cultured neonatal rat ventricular cardio-
myocytes [33]. Cardiac hypertrophy induced by the pres-
sure overload in heterozygous PPAR-γ-deficient mice 
is slightly more pronounced than that in the wild-type 
controls [34]. Studies on cardiomyocyte-specific PPAR-γ 
knockout mice have shown that PPAR-γ suppresses 
cardiac growth and embryonic gene expression and pro-
tects the heart from oxidative damage [35, 36]. Previous 
studies have shown that miR-27b regulates adipocyte 
differentiation and modulates inflammatory responses by 
targeting PPAR-γ [37, 38]. In our study, we observed that 
miR-27b targeted PPAR-γ in cardiomyocytes. Support-
ively, PPAR-γ expression was significantly downregu-
lated in hypertrophic hearts of miR-27b transgenic mice. 
This was further confirmed by the rescue experiment, 
which showed that overexpression of PPAR-γ decreased 
the hypertrophic growth caused by miR-27b overex-
pression. As miR-27b might target hundreds of mRNAs 
simultaneously, our results demonstrate that PPAR-γ is 
an important, but possibly not the only, target gene re-
sponsible for cardiac hypertrophy in miR-27b transgenic 
mice. 
In conclusion, our study identified that TGF-β-
regulated miR-27b is a regulator of cardiac hypertrophy, 
suggesting that antagonizing miR-27b might be a new 
therapeutic entry point for cardiac diseases.
Materials and Methods
Mouse strains
To obtain mice with targeted deletion of Smad4 gene in heart, 
homozygous mice for the floxed Smad4 allele (Smad4
flox/flox, ref-
erenced as Smad4
Co/Co before) [39] were bred with α-MHC-Cre 
transgenic mice, in which the expression of Cre recombinase is 
driven by the α-MHC promoter [6]. The genotyping was per-
formed as described [6].
Cloning and expression of miRNAs
A 500 bp genomic fragment encompassing the miR-27b coding 
region was amplified by PCR and ligated into adenoviral vectors to 
generate Ad-miR-27b using 293A cells. PCR primers for miR-27b 
were as follows: miR-27b sense: 5′-TTTCTCGAGGAAGATGCT-
CACCAGCCCTTTA-3′ and miR-27b antisense: 5′-TTTTCTA-
GAGCATCATCTTGCCAGCGACT-3′. The inhibitor of miR-27b 
used for target analysis was synthesized by Shanghai GenePharma 
Co., Ltd.
Isolation, culture and treatment of neonatal cardiomyocytes
Neonatal rat ventricular myocytes were isolated from 2-day-old 
pups, infected and stained as described [40].
Generation of miR-27b transgenic mice
A mouse genomic fragment flanking the miR-27b was ampli-
fied using primers 5′-TCACATTGCCAGGGATTACCAC-3′ and 
5′-TCAGCACGCTGTTTGCACTCTT-3′, then subcloned into 
a cardiac-specific expression plasmid containing the α-MHC 
promoter and human growth hormone (GH) poly (A) signal. To 
genotype the mouse, genomic DNA was isolated from mouse-
tail biopsies and analyzed by PCR using specific primers: 5′-Function of miR-27b in cardiac hypertrophy
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ATGACAGACAGATCCCTCCTATCTCC-3′ and 5′-TCAGCACG 
CTGTTTGCACTCTT-3′.
Western blot analysis
Western blot was carried out on myocardial extracts as de-
scribed [41]. 30 µg of proteins were electrophoresed on 12% SDS-
PAGE and transferred onto PVDF membranes. Immunoblotting 
was performed according to the manufacturer’s instructions using 
the following antibodies: anti-PPAR-γ, anti-Smad4, anti-PAI-1 and 
anti-GAPDH (Santa Cruz).
Transthoracic echocardiography and in vivo blood pressure 
measurement
Cardiac function and heart dimensions were evaluated by 
echocardiography and in vivo blood pressure measurements as de-
scribed [6].
Antagomir application on TAC models
TAC surgeries were performed on male C57BL/6 mice (8 
weeks old) as described [42]. Chemically modified antisense oli-
gonucleotides (antagomir) were synthesized by GenePharma Co., 
Ltd. Treatments started 2 weeks after TAC, and animals received 
0.2 ml saline, antagomir-27b (three injections in three consecutive 
days, 80 mg/kg body weight) via tail vein injections [31, 32].
Statistical analysis 
All statistical analyses were performed using SPSS software. 
Results are means ± SEM. Statistical differences were determined 
by Student’s t-test. P-value < 0.05 was considered significant.
Other methods including miRNA northern blot, plasmid and 
adenovirus constructions, isolation of cardiomyocytes, real-time 
PCR, luciferase reporter assay, histology and immunohistology are 
described in Supplementary information, Data S1.
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